Al-Dawaa (2070) Stock: Price, GoFinsa Rating and News
GoFinsa provides a guide to Al-Dawaa, listed under ticker 2070, including its economic sector and factors that may help investors assess the stock.
About Al-Dawaa and Its Business
Al-Dawaa operates in the manufacture and marketing of medicines and pharmaceutical products. Its business model is based on sales of medicines and healthcare products. When assessing its operations, relevant factors include pharmaceutical registrations, pricing and manufacturing costs. The company’s operating performance should be considered separately from movements in its share price.
Al-Dawaa Stock Information
Al-Dawaa shares trade on the Saudi Exchange under ticker 2070. The company belongs to the pharmaceuticals sector. Reviewing official disclosures and financial results can help investors understand the company’s position and business developments.
Al-Dawaa’s Activities and Company Information
The company is classified in the pharmaceuticals sector of the Saudi market. Annual reports and official disclosures can be used to examine its activities, revenue sources and operational developments.
The Pharmaceuticals Sector in the Saudi Economy
The performance of listed pharmaceuticals companies is linked to the nature of demand for their products and services, operating costs, competition, and economic and regulatory conditions. Companies may differ in how sensitive their businesses are to these factors.
How to Read the Company’s Financial Results
It is important to compare revenue, profit, cash flows and debt across several financial periods and to understand the reasons for changes rather than relying on a single quarter. Official announcements should also be reviewed for information about material events.
Factors That May Affect the Share Price
Al-Dawaa’s share price may be affected by the company’s results and disclosures, trends in the Saudi market, interest rates and investor expectations. Share-price movements alone do not indicate an improvement in operating performance.
Investment Risks
Potential risks include share-price volatility, changes in costs, weaker demand, competition and regulatory changes. Actual risks vary according to the company’s activities and financial position.
The Stock’s Investment Strength According to the GoFinsa Saudi Stocks Index
The rating recorded for the stock in the GoFinsa GFSI is 76%. This is an independent analytical rating, not a guarantee of profit or a personal recommendation to buy.
Investing in Saudi Stocks
The Saudi Exchange includes companies operating across a range of economic sectors. Investors can benefit from reviewing disclosures, comparing financial valuations, diversifying risk and setting an investment horizon before making a decision.
Following Company News
The latest disclosures and news relating to Al-Dawaa shares can be followed through the news sources and official data available on GoFinsa. Check the date of each item and how directly it relates to the company.
Al-Dawaa’s Reference Share Price
The recorded reference price is SAR 30.46 as of 2026-10-08. This is a historical price, not a live quote or a confirmed price for current trading.
Al-Dawaa’s Rating in the GoFinsa GFSI
The stock’s rating in the GoFinsa GFSI is 76%. This is a research rating from GoFinsa, not a recommendation to buy or sell.
About the Pharmaceuticals Sector
Al-Dawaa shares belong to the pharmaceuticals sector on the Saudi Exchange. Companies in the sector are affected by demand, competition, costs, and economic and regulatory conditions; their risk profiles and revenue sources differ.
Trading Through XTB and Associated Risks
What Does Al-Dawaa Do?
Al-Dawaa (2070) belongs to the pharmaceuticals sector. The company’s potential research scope includes the manufacture or marketing of medicines and healthcare preparations. The precise activities and any subsidiaries should be checked against the company’s latest official profile before publication.
Where Does Al-Dawaa’s Revenue Come From?
When analysing Al-Dawaa’s business model, review the following potential sources of income where supported by the company’s financial statements: sales of pharmaceutical products, distribution channels and exports, if any. Listing these items does not mean that each one actually contributes to the company’s revenue.
Factors That May Affect Al-Dawaa’s Performance
Relevant indicators to monitor in connection with Al-Dawaa’s activities include pharmaceutical registrations, pricing, production costs and competition. Compare trends in the company’s actual results across multiple periods, and do not infer growth or profitability without documented figures.
What to Check in the Annual Disclosure
When reviewing Al-Dawaa (2070), first identify the date of the latest annual report. Then read the description of its actual activities, operating segments and revenue-recognition policy. Review the notes to the financial statements rather than relying only on management’s summary; the notes may reveal obligations or events that are not apparent from the headline figures. Confirm the identity of the listed entity, its subsidiaries and the nature of their operations before attributing any activity or project to the company. A trend in the pharmaceuticals sector is not evidence of revenue growth at this company unless supported by its published results.
How to Distinguish Real Growth from Accounting Changes
To analyse Al-Dawaa, compare results for several periods of the same duration and pay attention to non-recurring items, reclassifications and changes in the consolidation scope. Higher revenue does not necessarily mean improved profitability if cost of sales or expenses have risen more quickly. Examine operating and net profit margins, then look for management’s explanation in the notes. If reliable, recent financial statements are unavailable, these remain analytical steps rather than a description of Al-Dawaa’s actual performance.
Cash Flows and the Ability to Fund Operations
When reviewing Al-Dawaa’s financial information, distinguish accounting profit from cash generated by operations. Examine net operating cash flows, changes in working capital, capital expenditure and financing costs. A company may report a profit while cash declines because of increases in receivables or inventory, or project payments. Conversely, cash flow may be temporarily affected by the timing of collections and payments. The company’s liquidity or solvency cannot be assessed without the relevant financial statements and notes.
Debt and Financing Costs: Key Questions
If Al-Dawaa has financing liabilities, start by identifying their maturity dates, the split between short- and long-term debt, borrowing costs and any contractual covenants. Assess how sensitive earnings and cash flows may be to interest-rate changes, taking into account whether financing is at fixed or variable rates. The significance of these questions depends on the company’s business model in the pharmaceuticals sector. This guide does not assume that the company has any particular level of debt or risk.
Comparing the Stock with Sector Peers Without Misleading Conclusions
For a fair comparison of Al-Dawaa, select companies with similar activities, revenue mixes, scale and regulatory environments. Compare revenue growth, margins, return on capital and cash flows, then consider differences in accounting and leverage. A lower price-to-earnings ratio than that of another company is not, by itself, enough to conclude that the stock is cheaper; differences may reflect growth expectations, risk or earnings quality. If a company is loss-making or has non-recurring profits, some valuation multiples may not be suitable for comparison.
How to Read the Reference Price and Its Date
The reference price shown in this guide is historical and dated; it is not a live bid or ask quote. When assessing Al-Dawaa, check which trading session the price relates to and whether capital changes, a stock split or distributions may affect historical comparisons. Do not confuse the previous close with the latest trade or the session’s average price. If market data is delayed, its date should be shown clearly, and no new daily trend should be inferred from an old figure.
Build Scenarios Instead of Predicting a Specific Price
Three scenarios can be used to study Al-Dawaa: improved business conditions, continuation of current conditions, and a decline in demand or margins. For each scenario, define measurable assumptions, such as sales volume, input costs or financing expenses, and compare the results with published financial statements when available. Do not set a price target without a valuation model and documented inputs, and do not present the positive scenario as an expected outcome. The purpose of this approach is to understand how sensitive an investment may be to new information.
Checklist Before Making an Investment Decision
Before dealing in Al-Dawaa shares, confirm ticker 2070, the company’s identity and the price date, and review the latest material disclosure, financial results and auditor’s notes, if available. Distinguish GoFinsa’s research rating from whether the investment is suitable for your personal circumstances. Define your investment horizon and risk tolerance, and consider your portfolio’s exposure to the pharmaceuticals sector. Review broker fees and the type of financial instrument: owning shares directly differs from trading derivatives or contracts for difference, which may carry additional risks.
أسئلة شائعة عن الشركة
What is Al-Dawaa’s stock ticker?
The stock trades on the Saudi Exchange under ticker 2070.
Which sector does Al-Dawaa belong to?
The stock belongs to the pharmaceuticals sector.
Is the GoFinsa index rating a buy recommendation?
No. The rating is an analytical tool and is not a personal investment recommendation or a guarantee of future performance.